NOVEL STEM TRIAL FOR CERVICAL SPINAL CORD INJURY TO
START WITH THE MILLER SCHOOL'S MIAMI PROJECT
October 2014 – A novel clinical trial using human neural stem cells for the treatment of cervical spinal cord injury is beginning at the Miller School of Medicine. Allan D. Levi, M.D., Ph.D, professor and Robert M. Buck Distinguished Chair in Neurological Surgery, is the principal investigator of the Pathway® Study, which is the first clinical study designed to evaluate both the safety and efficacy of transplanting stem cells into patients with traumatic injury to the cervical spinal cord.
The trial will use HuCNS-SC® cells, purified human neural stem cells developed by StemCells, Inc., a leader in the research and development of cell-based therapies for the treatment of disorders of the central nervous system. The trial will be conducted as a randomized, controlled, single-blind study and efficacy will be primarily measured by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms, and shoulders. The trial will follow the patients for one year from the time of enrollment.
Levi is a clinical researcher at The Miami Project to Cure Paralysis, a Center of Excellence at the Miller School, which is also conducting the first ever clinical trial of Schwann cell transplantation in patients with a new spinal cord injury among five other FDA approved clinical trials.
Friday - October 10, 2014
Neuroscience Center Seminar Series
LPLC 7th Floor Apex Auditorium
David H. Rowitch, MD, PhD
Department of Pediatrics and Neurological Surgery
Chief of Neonatology
University of California- San Francisco